A

Adcock Ingram Holdings Ltd
JSE:AIP

Watchlist Manager
Adcock Ingram Holdings Ltd
JSE:AIP
Watchlist
Price: 7 480.0003 Zac Market Closed
Market Cap: 12.1B ZAR

Net Margin

8.8%
Current
Declining
by 0.1%
vs 3-y average of 8.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
8.8%
=
Net Income
858.5m
/
Revenue
9.8B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
8.8%
=
Net Income
Zac858.5m
/
Revenue
9.8B

Peer Comparison

Country Company Market Cap Net
Margin
ZA
Adcock Ingram Holdings Ltd
JSE:AIP
12.1B ZAR
Loading...
US
Eli Lilly and Co
NYSE:LLY
1.1T USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
564.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
287.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
294.9B USD
Loading...
CH
Novartis AG
SIX:NOVN
229.6B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
215B GBP
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
153.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
98.9B EUR
Loading...

Market Distribution

In line with most companies in South Africa
Percentile
40th
Based on 27 companies
40th percentile
8.8%
Low
-785% — -2.1%
Typical Range
-2.1% — 27.2%
High
27.2% — 204.2%
Distribution Statistics
South Africa
Min -785%
30th Percentile -2.1%
Median 24.6%
70th Percentile 27.2%
Max 204.2%

Adcock Ingram Holdings Ltd
Glance View

Market Cap
12.1B Zac
Industry
Pharmaceuticals

Nestled in the competitive landscape of the pharmaceutical industry, Adcock Ingram Holdings Ltd. stands as a testament to resilience and evolution. Originating in South Africa, the company has built a legacy that combines a strong local presence with strategic global aspirations. Adcock Ingram’s journey is marked by an adaptive approach that blends innovation with consumer health needs. Its primary revenue streams flow from the development, manufacturing, and distribution of a wide array of healthcare products, including prescription medicines, over-the-counter formulations, and hospital medications. By maintaining a robust supply chain and nurturing partnerships both locally and internationally, the company ensures the steady availability of essential healthcare products across markets. The company’s recipe for success is enriched by a deep-rooted commitment to quality and research-driven practices. By investing in cutting-edge manufacturing facilities and a well-structured distribution network, Adcock Ingram manages to sustain efficiency and scale. This approach does not merely hinge on the core pharmaceutical business but extends to leveraging diverse consumer brands across various segments such as personal care and nutritional products. Their diverse portfolio not only mitigates risks associated with the volatile pharmaceutical industry but also aligns with the ever-evolving consumer health trends. In essence, Adcock Ingram thrives by intertwining strategic foresight with robust operational excellence, steadfastly serving the health and well-being of its customers.

AIP Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
8.8%
=
Net Income
858.5m
/
Revenue
9.8B
What is Adcock Ingram Holdings Ltd's current Net Margin?

The current Net Margin for Adcock Ingram Holdings Ltd is 8.8%, which is below its 3-year median of 8.9%.

How has Net Margin changed over time?

Over the last 3 years, Adcock Ingram Holdings Ltd’s Net Margin has decreased from 9.2% to 8.8%. During this period, it reached a low of 7.9% on Dec 31, 2024 and a high of 9.8% on Jun 30, 2023.

Back to Top